Literature DB >> 16242644

Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.

Isidro Ferrer1, Marta Barrachina, Berta Puig, M Martínez de Lagrán, Eulalia Martí, Jesús Avila, Mara Dierssen.   

Abstract

DYRK1A, dual-specificity tyrosine-regulated kinase 1A, maps to human chromosome 21 within the Down syndrome (DS) critical region. Dyrk1 phosphorylates the human microtubule-associated protein tau at Thr212 in vitro, a residue that is phosphorylated in fetal tau and hyper-phosphorylated in Alzheimer disease (AD) and tauopathies, including Pick disease (PiD). Furthermore, phosphorylation of Thr212 primes tau for phosphorylation by glycogen synthase kinase 3 (GSK-3). The present study examines Dyrk1A in the cerebral cortex of sporadic AD, adult DS with associated AD, and PiD. Increased Dyrk1A immunoreactivity has been found in the cytoplasm and nuclei of scattered neurons of the neocortex, entorhinal cortex, and hippocampus in AD, DS, and PiD. Dyrk1A is found in sarkosyl-insoluble fractions which are enriched in phosphorylated tau in AD brains, thus suggesting a possible association of Dyrk1A with neurofibrillary tangle pathology. Yet, no clear relationship has been observed between tau phosphorylation at Thr212, and GSK-3 and Dyrk1A expression in diseased brains. Transgenic mice bearing a triple tau mutation (G272V, P301L, and R406W) and expressing hyper-phosphoyrylated tau in neurons of the entorhinal cortex, hippocampus, and cerebral neocortex show increased expression of Dyrk1A in individual neurons in the same regions. However, transgenic mice over-expressing Dyrk1A do not show increased phosphorylation of tau at Thr212, thus suggesting that Dyrk1A over-expression does not trigger per se hyper-phosphorylation of tau at Thr212 in vivo. The present observations indicate modifications in the expression of constitutive Dyrk1A in the cytoplasm and nuclei of neurons in various neurodegenerative diseases associated with tau phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242644     DOI: 10.1016/j.nbd.2005.03.020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  53 in total

1.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.

Authors:  Jerzy Wegiel; Karol Dowjat; Wojciech Kaczmarski; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur Kolecka; Jarek Wegiel; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Cheng-Xin Gong; Fei Liu; Tatyana Adayev; Mo-Chou Chen-Hwang; Yu-Wen Hwang
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

2.  Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.

Authors:  Eric D Hamlett; Edward J Goetzl; Aurélie Ledreux; Vitaly Vasilevko; Heather A Boger; Angela LaRosa; David Clark; Steven L Carroll; María Carmona-Iragui; Juan Fortea; Elliott J Mufson; Marwan Sabbagh; Abdul H Mohammed; Dean Hartley; Eric Doran; Ira T Lott; Ann-Charlotte Granholm
Journal:  Alzheimers Dement       Date:  2016-10-15       Impact factor: 21.566

3.  Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.

Authors:  Karol Dowjat; Tatyana Adayev; Wojciech Kaczmarski; Jerzy Wegiel; Yu-Wen Hwang
Journal:  J Neuropathol Exp Neurol       Date:  2012-12       Impact factor: 3.685

Review 4.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

5.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

6.  Molecular rescue of DYRK1A overexpression in cystathionine beta synthase-deficient mouse brain by enriched environment combined with voluntary exercise.

Authors:  Benoit Souchet; Alizée Latour; Yuchen Gu; Fabrice Daubigney; Jean-Louis Paul; Jean-Maurice Delabar; Nathalie Janel
Journal:  J Mol Neurosci       Date:  2014-05-13       Impact factor: 3.444

7.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.

Authors:  Nana Jin; Xiaomin Yin; Jianlan Gu; Xinhua Zhang; Jianhua Shi; Wei Qian; Yuhua Ji; Maohong Cao; Xiaosong Gu; Fei Ding; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

8.  DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.

Authors:  José Luis Vázquez-Higuera; Pascual Sánchez-Juan; Eloy Rodríguez-Rodríguez; Ignacio Mateo; Ana Pozueta; Ana Frank; Isabel Sastre; Fernando Valdivieso; José Berciano; María J Bullido; Onofre Combarros
Journal:  BMC Med Genet       Date:  2009-12-08       Impact factor: 2.103

9.  Generation of a panel of antibodies against proteins encoded on human chromosome 21.

Authors:  Frances K Wiseman; Olivia Sheppard; Jacqueline M Linehan; Sebastian Brandner; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  J Negat Results Biomed       Date:  2010-08-20

10.  Anticancer alkaloid lamellarins inhibit protein kinases.

Authors:  Dianne Baunbaek; Nolwenn Trinkler; Yoan Ferandin; Olivier Lozach; Poonsakdi Ploypradith; Somsak Rucirawat; Fumito Ishibashi; Masatomo Iwao; Laurent Meijer
Journal:  Mar Drugs       Date:  2008-10-07       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.